Clinical trials: Oral Cavity Carcinoma
Renal Cell Cancer, Prostate Cancer
Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention
This study evaluates a smart phone based mobile application designed for patients with Renal Cell and Prostate Cancer taking oral anti-cancer medications.
- Conditions
- Renal Cell Cancer, Prostate Cancer, Effects of Chemotherapy
- Trial name
- CORA (NCT02375776)
- Testing
- CORA- Device:smartphones"
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Current Smoker, Head and Neck Squamous Cell Carcinoma
Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
This pilot randomized clinical trial studies how well bupropion hydrochloride works compared with patient's choice for quitting smoking in patients with squamous cell head and neck cancer undergoing radiation therapy with or…
- Conditions
- Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT02582008
- Testing
- Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Wake Forest University Health Sciences
Non-small Cell Lung Cancer
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
This is an open-label, single centre, Phase I study to determine the brain exposure of [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
- Trial name
- ODIN-BM (NCT03463525)
- Testing
- Osimertinib, [11C]osimertinib
- Where
- Sweden
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Nasopharyngeal Carcinoma
Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma
This is a prospective multicenter study with patients with delayed dysphagia after radiotherapy for NPC. Patients enrolled are randomly divided equally into the observation group and the control group.
- Trial name
- NCT06248840
- Testing
- Intermittent Oral-esophageal Tube Feeding, nasogastric tube feeding
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Zeng Changhao
Head and Neck Cancer
Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- CKNO-RERT (NCT00738868)
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Oscar Lambret
Oral Cavity Squamous Cell Carcinoma
Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)
This is a study of oral nisin administration in patients with OSCC who are undergoing complete surgical resection surgery with or without adjuvant radiation/chemoradiation as part of their routine care at the University of…
- Trial name
- NCT06097468
- Testing
- NisinZ® P, Surgery (non-interventional, standard of care)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Lip and Oral Cavity Cancer, Oral Leukoplakia
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
This randomized phase II trial is studying how well Bowman-Birk inhibitor concentrate works in preventing cancer in patients with oral leukoplakia.
- Conditions
- Lip and Oral Cavity Cancer, Oral Leukoplakia, Oropharyngeal Cancer, Tongue Cancer
- Trial name
- NCT00330382
- Testing
- Bowman-Birk inhibitor concentrate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 325 people
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma, Hedgehog Pathway
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.
Patients with localized basocellular carcinoma of the skin, will receive oral Itraconazole, 200 mg twice daily, for 60 days, prior to curative intent surgery.
- Trial name
- NCT03972748
- Testing
- Itraconazole 200 mg
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Stomatitis
Recombinant Bovine Basic Fibroblast Growth Factor for the Treatment of Radiation Induced Oral Mucositis
Radiation therapy is one of the treatments for Nasopharyngeal carcinoma . The most common side effects of post-radiation may be radiation-induced oral mucositis .
- Trial name
- NCT03778008
- Testing
- Recombinant bovine basic fibroblast growth factor, Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Head and Neck Cancer
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00030576
- Testing
- cisplatin, erlotinib hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 51 people
- Sponsor
- University Health Network, Toronto
Oral Squamous Cell Carcinoma
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
The purpose of this study is to investigate the safety and feasibility of neoadjuvant PD-1 blockade alone or neoadjuvant PD-1 blockade plus TPF induction chemotherapy in subjects with resectable local advanced oral squamous cell…
- Trial name
- NEOPBOSCC (NCT04649476)
- Testing
- Camrelizumab, Camrelizumanb plus TPF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Hospital of Stomatology, Wuhan University
Cervical Cancer, Ovarian Cancer
Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients who have refractory…
- Trial name
- NCT00002478
- Testing
- etoposide
- Where
- 47 sites in United States
- Sponsor
- Gynecologic Oncology Group
Head and Neck Cancer, Paranasal Sinus Cancer
Adaptive Radiotherapy for Head and Neck Cancer
The purpose of this study is to demonstrate that adaptive radiotherapy (ART) in head and neck cancer patients are comparable to historical controls in head and neck patients undergoing standard intensity-modulated radiation…
- Conditions
- Head and Neck Cancer, Paranasal Sinus Cancer, Oropharynx Cancer, Oral Cavity Cancer
- Trial name
- NCT03096808
- Testing
- Adaptive Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Oral Cavity Cancer
Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae
This is a phase 1b, multicenter, non-randomized prospective study involving an innovation phase (IDEAL-1) followed by a prospective development phase (IDEAL-2A) designed to evaluate the safety and feasibility of…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- LAMBEAU STEPA (NCT05757817)
- Testing
- Oropharyngeal or oral cavity reconstruction
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut Claudius Regaud
Oral Squamous Cell Carcinoma
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
This study aims to investigate the efficacy and safety of neoadjuvant Toripalimab combined with Nimotuzumab in primary limited stage oral squamous cell carcinoma prior to radical therapy.
- Trial name
- NCT05803915
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking Union Medical College Hospital
Carcinoma, Non-Small-Cell Lung
BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I
To confirm the safety of BIBF 1120 at a dose level up to 200 mg x 2/day (i.e., overseas recommended Phase III dose for combination treatment) with standard therapy of docetaxel (60 mg/m2 and 75 mg/m2) in Japanese advanced non…
- Trial name
- NCT00876460
- Testing
- BIBF 1120 M + docetaxel M, BIBF 1120 M + docetaxel H, BIBF 1120 H + docetaxel H
- Where
- 2 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Oral Cavity Squamous Cell Carcinoma
Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
This clinical trial studies how well helical computed tomography (CT), positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), and cone beam computed tomography (CBCT) work alone or in combination in predicting…
- Trial name
- NCT03053960
- Testing
- Computed Tomography, Positron Emission Tomography and Computed Tomography Scan, Cone-Beam Computed Tomography
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01175980
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine and capecitabine use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00058318
- Testing
- capecitabine, gemcitabine hydrochloride
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Cancer
S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00336947
- Testing
- tegafur-gimeracil-oteracil potassium, tegafur-uracil, adjuvant therapy
- Where
- 48 sites in Japan
- Volunteers
- 500 people
- Sponsor
- Yokohama City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.